Atopic eczema

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 16, Issue 1, 2016, Pages 66-69

  Brown, Sara J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIECZEMA AGENT; BIOLOGICAL PRODUCT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EMOLLIENT AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID;

ARTICLE; ATOPIC DERMATITIS; BIOLOGICAL THERAPY; COMORBIDITY; DISEASE CONTROL; EMERGENCY MEDICINE; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); STEROID THERAPY; SYSTEMIC THERAPY; ULTRAVIOLET RADIATION; ADULT; CHILD; ECZEMA; PATHOLOGY; SKIN;

ADULT; CHILD; DERMATITIS, ATOPIC; ECZEMA; HUMANS; SKIN;

EID: 84970937382     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.16-1-66     Document Type: Article

References (20)

1. Johansson SG, Bieber T, Dahl R et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
2. Beattie P, Lewis-Jones M. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006; 155: 145-51.
3. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24.
4. Brown SJ, McLean WH. One remarkable molecule: filaggrin . J Invest Dermatol 2012; 132: 751-62.
5. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365: 1315-27.
6. Deckert S, Kopkow C, Schmitt J. Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy 2014; 69: 37-45.
7. Nankervis H, Pynn EV, Boyle RJ et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev 2015; 1: CD008426.
8. No authors listed. Bath emollients for atopic eczema: why use them? Drug Ther Bull 2007; 45: 73-5.
9. Proudfoot LE, Powell AM, Ayis S e t al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013; 169: 901-9.
10. Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol 2013; 132: 774-e6.
11. Madhok V, Futamura M, Thomas KS, Barbarot S. What's new in atopic eczema? An analysis of systematic reviews published in 2012 and 2013. Part 2. Treatment and prevention. Clin Exp Dermatol 2015; 40: 349-54; quiz 54-5.
12. Kong HH, Oh J, Deming C, Conlan S et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850-9.
13. Smith FJ, Irvine AD, Terron-Kwiatkowski A e t al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006; 38: 337-42.
14. Palmer CN, Irvine AD, Terron-Kwiatkowski A e t al. Common lossof-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genet 2006; 38: 441-6.
15. Rodriguez E, Baurecht H, Herberich E et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol 2009; 123: 1361-70.e7.
16. Kelleher M, Dunn-Galvin A, Hourihane JO et al. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol 2015; 135: 930-5.e1.
17. Simpson EL, Chalmers JR, Hanifin JM et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014; 134: 818-23.
18. Beck LA, Thaci D, Hamilton JD et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-9.
19. Thaci D, Simpson EL, Beck LA e t al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2015, epub ahead of print.
20. Grice EA. The intersection of microbiome and host at the skin interface: genomic-and metagenomic-based insights. Genome Res 2015; 25: 1514-20.